Literature DB >> 18172262

Axl and growth arrest-specific gene 6 are frequently overexpressed in human gliomas and predict poor prognosis in patients with glioblastoma multiforme.

Markus Hutterer1, Pjotr Knyazev, Ariane Abate, Markus Reschke, Hans Maier, Nadia Stefanova, Tatjana Knyazeva, Verena Barbieri, Markus Reindl, Armin Muigg, Herwig Kostron, Guenther Stockhammer, Axel Ullrich.   

Abstract

PURPOSE: The receptor tyrosine kinase Axl has recently been identified as a critical element in the invasive properties of glioma cell lines. However, the effect of Axl and its ligand growth arrest--specific gene 6 (Gas6) in human gliomas is still unknown. EXPERIMENTAL
DESIGN: Axl and Gas6 expression was studied in 42 fresh-frozen and 79 paraffin-embedded glioma specimens by means of reverse transcription-PCR and immunohistochemistry. The prognostic value of Axl and Gas6 expression was evaluated using a population-based tissue microarray derived from a cohort of 55 glioblastoma multiforme (GBM) patients.
RESULTS: Axl and Gas6 were detectable in gliomas of malignancy grades WHO 2 to 4. Moderate to high Axl mRNA expression was found in 61%, Axl protein in 55%, Gas6 mRNA in 81%, and Gas6 protein in 74% of GBM samples, respectively. GBM patients with high Axl expression and Axl/Gas6 coexpression showed a significantly shorter time to tumor progression and an association with poorer overall survival. Comparative immunohistochemical studies showed that Axl staining was most pronounced in glioma cells of pseudopalisades and reactive astrocytes. Additionally, Axl/Gas6 coexpression was observed in glioma cells and tumor vessels. In contrast, Axl staining was not detectable in nonneoplastic brain tissue and Gas6 was strongly expressed in neurons.
CONCLUSIONS: In human gliomas, Axl and Gas6 are frequently overexpressed in both glioma and vascular cells and predict poor prognosis in GBM patients. Our results indicate that specific targeting of the Axl/Gas6 signaling pathway may represent a potential new approach for glioma treatment.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18172262     DOI: 10.1158/1078-0432.CCR-07-0862

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  131 in total

1.  Overexpression of receptor tyrosine kinase Axl promotes tumor cell invasion and survival in pancreatic ductal adenocarcinoma.

Authors:  Xianzhou Song; Hua Wang; Craig D Logsdon; Asif Rashid; Jason B Fleming; James L Abbruzzese; Henry F Gomez; Douglas B Evans; Huamin Wang
Journal:  Cancer       Date:  2010-10-04       Impact factor: 6.860

2.  Inhibition of Mer and Axl receptor tyrosine kinases in astrocytoma cells leads to increased apoptosis and improved chemosensitivity.

Authors:  Amy K Keating; Grace K Kim; Ashley E Jones; Andrew M Donson; Kathryn Ware; Jean M Mulcahy; Dana B Salzberg; Nicholas K Foreman; Xiayuan Liang; Andrew Thorburn; Douglas K Graham
Journal:  Mol Cancer Ther       Date:  2010-04-27       Impact factor: 6.261

3.  NGAL and NGALR are frequently overexpressed in human gliomas and are associated with clinical prognosis.

Authors:  Ming-Fa Liu; Tao Jin; Jin-Hui Shen; Zhong-Ying Shen; Zhi-Chao Zheng; Zeng-Liang Zhang; Li-Yan Xu; En-Min Li; Hai-Xiong Xu
Journal:  J Neurooncol       Date:  2010-12-24       Impact factor: 4.130

Review 4.  The role of TAM family receptors and ligands in the nervous system: From development to pathobiology.

Authors:  Bridget Shafit-Zagardo; Ross C Gruber; Juwen C DuBois
Journal:  Pharmacol Ther       Date:  2018-03-04       Impact factor: 12.310

5.  Response to "reply to [18F]-fluoro-ethyl-L-tyrosine PET: a valuable diagnostic tool in neuro-oncology, but not all that glitters is glioma" by Hutterer et al.

Authors:  Markus Hutterer; Martha Nowosielski; Daniel Putzer; Christian la Fougère; Irene J Virgolini; Andreas H Jacobs; Günther Stockhammer
Journal:  Neuro Oncol       Date:  2013-06-19       Impact factor: 12.300

6.  First Axl inhibitor enters clinical trials.

Authors:  Cormac Sheridan
Journal:  Nat Biotechnol       Date:  2013-09       Impact factor: 54.908

Review 7.  Biology of the TAM receptors.

Authors:  Greg Lemke
Journal:  Cold Spring Harb Perspect Biol       Date:  2013-11-01       Impact factor: 10.005

8.  Gas6/Axl pathway is activated in chronic liver disease and its targeting reduces fibrosis via hepatic stellate cell inactivation.

Authors:  Cristina Bárcena; Milica Stefanovic; Anna Tutusaus; Leonel Joannas; Anghara Menéndez; Carmen García-Ruiz; Pau Sancho-Bru; Montserrat Marí; Joan Caballeria; Carla V Rothlin; José C Fernández-Checa; Pablo García de Frutos; Albert Morales
Journal:  J Hepatol       Date:  2015-04-20       Impact factor: 25.083

9.  Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival.

Authors:  Christine Gjerdrum; Crina Tiron; Torill Høiby; Ingunn Stefansson; Hallvard Haugen; Tone Sandal; Karin Collett; Shan Li; Emmet McCormack; Bjørn Tore Gjertsen; David R Micklem; Lars A Akslen; Carlotta Glackin; James B Lorens
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-28       Impact factor: 11.205

10.  FOXD1-ALDH1A3 Signaling Is a Determinant for the Self-Renewal and Tumorigenicity of Mesenchymal Glioma Stem Cells.

Authors:  Peng Cheng; Jia Wang; Indrayani Waghmare; Stefania Sartini; Vito Coviello; Zhuo Zhang; Sung-Hak Kim; Ahmed Mohyeldin; Marat S Pavlyukov; Mutsuko Minata; Claudia L L Valentim; Rishi Raj Chhipa; Krishna P L Bhat; Biplab Dasgupta; Concettina La Motta; Madhuri Kango-Singh; Ichiro Nakano
Journal:  Cancer Res       Date:  2016-08-28       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.